F. Cardoso and M. Piccart, The best use of chemotherapy in the adjuvant setting, The Breast, vol.12, issue.6, pp.522-528, 2003.
DOI : 10.1016/S0960-9776(03)00161-9

H. Kuerer, L. Newman, T. Smith, F. Ames, and K. Hunt, Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.17, issue.2, pp.460-469, 1999.
DOI : 10.1200/JCO.1999.17.2.460

P. Bertheau, F. Lerebours, N. Mounier, A. De-roquancourt, and M. Espie, Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer, Oncology Reports, vol.14, pp.513-520, 2005.
DOI : 10.3892/or.14.2.513

M. Kaufmann, G. Hortobagyi, A. Goldhirsch, S. Scholl, and A. Makris, Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update, Journal of Clinical Oncology, vol.24, issue.12, pp.1940-1949, 2006.
DOI : 10.1200/JCO.2005.02.6187

M. Kaufmann, G. Von-minckwitz, R. Smith, V. Valero, and L. Gianni, International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations, Journal of Clinical Oncology, vol.21, issue.13, pp.2600-2608, 2003.
DOI : 10.1200/JCO.2003.01.136

J. Chang, E. Wooten, A. Tsimelzon, S. Hilsenbeck, and M. Gutierrez, Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, The Lancet, vol.362, issue.9381, pp.362-369, 2003.
DOI : 10.1016/S0140-6736(03)14023-8

R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, and M. Cristofanilli, Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy, Clinical Cancer Research, vol.11, issue.16, pp.5678-5685, 2005.
DOI : 10.1158/1078-0432.CCR-04-2421

S. Cleator, A. Tsimelzon, A. Ashworth, M. Dowsett, and T. Dexter, Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance, Breast Cancer Research and Treatment, vol.22, issue.3, pp.229-233, 2006.
DOI : 10.1007/s10549-005-9009-7

S. Lowe, E. Cepero, and G. Evan, Intrinsic tumour suppression, Nature, vol.35, issue.7015, pp.307-315, 2004.
DOI : 10.1038/nature03098

F. Bunz, P. Hwang, C. Torrance, T. Waldman, and Y. Zhang, Disruption of p53 in human cancer cells alters the responses to therapeutic agents, Journal of Clinical Investigation, vol.104, issue.3, pp.263-269, 1999.
DOI : 10.1172/JCI6863

H. Dohner, K. Fischer, M. Bentz, K. Hansen, and A. Benner, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood, vol.85, pp.1580-1589, 1995.

A. Rosenwald, E. Chuang, R. Davis, A. Wiestner, and A. Alizadeh, Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response, Blood, vol.104, issue.5, pp.1428-1434, 2004.
DOI : 10.1182/blood-2003-09-3236

T. Aas, A. Borresen, S. Geisler, B. Smith-sorensen, and H. Johnsen, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nature Medicine, vol.19, issue.7, pp.811-814, 1996.
DOI : 10.1016/0959-8049(94)00213-O

L. Miller, J. Smeds, J. George, V. Vega, and L. Vergara, From The Cover: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival, Proceedings of the National Academy of Sciences, vol.102, issue.38, pp.13550-13555, 2005.
DOI : 10.1073/pnas.0506230102

D. Kandioler-eckersberger, C. Ludwig, M. Rudas, S. Kappel, and E. Janschek, TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients, Clin Cancer Res, vol.6, pp.50-56, 2000.

M. Olivier, A. Langerod, P. Carrieri, J. Bergh, and S. Klaar, The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1157-1167, 2006.
DOI : 10.1158/1078-0432.CCR-05-1029

V. Malamou-mitsi, H. Gogas, U. Dafni, A. Bourli, and T. Fillipidis, Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Annals of Oncology, vol.17, issue.10, pp.1504-1511, 2006.
DOI : 10.1093/annonc/mdl147

P. Chappuis, A. Estreicher, B. Dieterich, H. Bonnefoi, and M. Otter, Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay, International Journal of Cancer, vol.44, issue.6, pp.587-593, 1999.
DOI : 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8

P. Cottu, L. Zelek, J. Extra, M. Espie, and L. Mignot, High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients, Annals of Oncology, vol.10, issue.7, pp.795-801, 1999.
DOI : 10.1023/A:1008353904351

L. Sobin and W. Ceditors, TNM: Classification of malignant tumours, 2002.
DOI : 10.1002/0471463752

C. Elston and I. Ellis, pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, pp.403-410, 1991.
DOI : 10.1016/0277-5379(88)90171-X

P. Bertheau, F. Plassa, M. Espie, E. Turpin, and A. De-roquancourt, Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy, The Lancet, vol.360, issue.9336, pp.852-854, 2002.
DOI : 10.1016/S0140-6736(02)09969-5

J. Flaman, T. Frebourg, V. Moreau, F. Charbonnier, and C. Martin, A simple p53 functional assay for screening cell lines, blood, and tumors., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3963-3967, 1995.
DOI : 10.1073/pnas.92.9.3963

F. Waridel, A. Estreicher, L. Bron, J. Flaman, and C. Fontolliet, Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract, Oncogene, vol.14, issue.2, pp.163-169, 1997.
DOI : 10.1038/sj.onc.1200812

M. Van-de-rijn, C. Perou, R. Tibshirani, P. Haas, and O. Kallioniemi, Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome, The American Journal of Pathology, vol.161, issue.6, pp.1991-1996, 2002.
DOI : 10.1016/S0002-9440(10)64476-8

T. Nielsen, F. Hsu, K. Jensen, M. Cheang, and G. Karaca, Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-5374, 2004.
DOI : 10.1158/1078-0432.CCR-04-0220

S. Han, S. Ahn, K. Park, B. Bae, and K. Kim, p16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy, Breast Cancer Research and Treatment, vol.16, issue.3, pp.205-212, 2001.
DOI : 10.1023/A:1013047413895

K. Milde-langosch, A. Bamberger, G. Rieck, B. Kelp, and T. Loning, Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype, Breast Cancer Research and Treatment, vol.93, issue.1, pp.61-70, 2001.
DOI : 10.1023/A:1010623308275

R. Emig, A. Magener, V. Ehemann, A. Meyer, and F. Stilgenbauer, Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation, British Journal of Cancer, vol.78, issue.12, pp.1661-1668, 1998.
DOI : 10.1038/bjc.1998.739

C. Sotiriou, S. Neo, L. Mcshane, E. Korn, and P. Long, Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proceedings of the National Academy of Sciences, vol.100, issue.18, pp.10393-10398, 2003.
DOI : 10.1073/pnas.1732912100

J. Andersson, L. Larsson, S. Klaar, L. Holmberg, and J. Nilsson, Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF, Annals of Oncology, vol.16, issue.5, pp.743-748, 2005.
DOI : 10.1093/annonc/mdi150

C. Perou, T. Sorlie, M. Eisen, M. Van-de-rijn, and S. Jeffrey, Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000.
DOI : 10.1038/35021093

T. Sorlie, C. Perou, R. Tibshirani, T. Aas, and S. Geisler, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001.
DOI : 10.1073/pnas.191367098

G. Mcgill and D. Fisher, p53 and cancer therapy: a double-edged sword, Journal of Clinical Investigation, vol.104, issue.3, pp.223-225, 1999.
DOI : 10.1172/JCI7861

L. Van-putten and P. Lelieved, Factors determining cell killing by chemotherapeutic agents In Vivo???II., European Journal of Cancer (1965), vol.7, issue.1, pp.11-17, 1971.
DOI : 10.1016/0014-2964(71)90089-2

O. Modlich, H. Prisack, M. Munnes, W. Audretsch, and H. Bojar, Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease, Clinical Cancer Research, vol.10, issue.19, pp.6418-6431, 2004.
DOI : 10.1158/1078-0432.CCR-04-1031

M. Nitta, O. Kobayashi, S. Honda, T. Hirota, and S. Kuninaka, Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents, Oncogene, vol.23, issue.39, pp.6548-6558, 2004.
DOI : 10.1038/sj.onc.1207873

M. Tanner, J. Isola, T. Wiklund, B. Erikstein, and P. Kellokumpu-lehtinen, ???Amplified Breast Cancer: Scandinavian Breast Group Trial 9401, Journal of Clinical Oncology, vol.24, issue.16, pp.2428-2436, 2006.
DOI : 10.1200/JCO.2005.02.9264

A. Berns, Cancer biology: Can less be more for p53?, Nature, vol.2, issue.7108, pp.153-154, 2006.
DOI : 10.1038/443153a

S. Singh, C. Hawkins, I. Clarke, J. Squire, and J. Bayani, Identification of human brain tumour initiating cells, Nature, vol.64, issue.7015, pp.396-401, 2004.
DOI : 10.1038/nature03128

B. Weaver and D. Cleveland, Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death, Cancer Cell, vol.8, issue.1, pp.7-12, 2005.
DOI : 10.1016/j.ccr.2005.06.011

J. Mieog, J. Van-der-hage, M. Van-de-vijver, and C. Van-de-velde, Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression, European Journal of Cancer, vol.42, issue.10, pp.1369-1379, 2006.
DOI : 10.1016/j.ejca.2006.01.054

S. Banerjee, J. Reis-filho, S. Ashley, D. Steele, and A. Ashworth, Basal-like breast carcinomas: clinical outcome and response to chemotherapy, Journal of Clinical Pathology, vol.59, issue.7, pp.729-735, 2006.
DOI : 10.1136/jcp.2005.033043

M. Citron, D. Berry, C. Cirrincione, C. Hudis, and E. Winer, Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, Journal of Clinical Oncology, vol.21, issue.8, pp.1431-1439, 2003.
DOI : 10.1200/JCO.2003.09.081